Cargando…

Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt

OBJECTIVES: The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. METHODS: The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammam, Nevin, Tharwat, Samar, Shereef, Rawhya R. El, Elsaman, Ahmed M., Khalil, Noha M., Fathi, Hanan M., Salem, Mohamed N., El-Saadany, Hanan M., Samy, Nermeen, El-Bahnasawy, Amany S., Abdel-Fattah, Yousra H., Amer, Marwa A., ElShebini, Emad, El-Shanawany, Amira T., El-Hammady, Dina H., Noor, Rasha Abdel, ElKhalifa, Marwa, Ismail, Faten, Fawzy, Rasha M., El-Najjar, Amany R., Selim, Zahraa I., Abaza, Nouran M., Radwan, Ahmed R., Elazeem, Mervat IAbd, Mohsen, Wael Abdel, Moshrif, Abdel Hafeez, Mohamed, Eman F., Aglan, Loay I., Senara, Soha, Ibrahim, Maha E., Khalifa, Iman, Owaidy, Rasha El, Fakharany, Noha El., Mohammed, Reem Hamdy A., Gheita, Tamer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269986/
https://www.ncbi.nlm.nih.gov/pubmed/34244818
http://dx.doi.org/10.1007/s00296-021-04941-0
_version_ 1783720703941410816
author Hammam, Nevin
Tharwat, Samar
Shereef, Rawhya R. El
Elsaman, Ahmed M.
Khalil, Noha M.
Fathi, Hanan M.
Salem, Mohamed N.
El-Saadany, Hanan M.
Samy, Nermeen
El-Bahnasawy, Amany S.
Abdel-Fattah, Yousra H.
Amer, Marwa A.
ElShebini, Emad
El-Shanawany, Amira T.
El-Hammady, Dina H.
Noor, Rasha Abdel
ElKhalifa, Marwa
Ismail, Faten
Fawzy, Rasha M.
El-Najjar, Amany R.
Selim, Zahraa I.
Abaza, Nouran M.
Radwan, Ahmed R.
Elazeem, Mervat IAbd
Mohsen, Wael Abdel
Moshrif, Abdel Hafeez
Mohamed, Eman F.
Aglan, Loay I.
Senara, Soha
Ibrahim, Maha E.
Khalifa, Iman
Owaidy, Rasha El
Fakharany, Noha El.
Mohammed, Reem Hamdy A.
Gheita, Tamer A.
author_facet Hammam, Nevin
Tharwat, Samar
Shereef, Rawhya R. El
Elsaman, Ahmed M.
Khalil, Noha M.
Fathi, Hanan M.
Salem, Mohamed N.
El-Saadany, Hanan M.
Samy, Nermeen
El-Bahnasawy, Amany S.
Abdel-Fattah, Yousra H.
Amer, Marwa A.
ElShebini, Emad
El-Shanawany, Amira T.
El-Hammady, Dina H.
Noor, Rasha Abdel
ElKhalifa, Marwa
Ismail, Faten
Fawzy, Rasha M.
El-Najjar, Amany R.
Selim, Zahraa I.
Abaza, Nouran M.
Radwan, Ahmed R.
Elazeem, Mervat IAbd
Mohsen, Wael Abdel
Moshrif, Abdel Hafeez
Mohamed, Eman F.
Aglan, Loay I.
Senara, Soha
Ibrahim, Maha E.
Khalifa, Iman
Owaidy, Rasha El
Fakharany, Noha El.
Mohammed, Reem Hamdy A.
Gheita, Tamer A.
author_sort Hammam, Nevin
collection PubMed
description OBJECTIVES: The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. METHODS: The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. RESULTS: 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). CONCLUSIONS: The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00296-021-04941-0.
format Online
Article
Text
id pubmed-8269986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-82699862021-07-09 Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt Hammam, Nevin Tharwat, Samar Shereef, Rawhya R. El Elsaman, Ahmed M. Khalil, Noha M. Fathi, Hanan M. Salem, Mohamed N. El-Saadany, Hanan M. Samy, Nermeen El-Bahnasawy, Amany S. Abdel-Fattah, Yousra H. Amer, Marwa A. ElShebini, Emad El-Shanawany, Amira T. El-Hammady, Dina H. Noor, Rasha Abdel ElKhalifa, Marwa Ismail, Faten Fawzy, Rasha M. El-Najjar, Amany R. Selim, Zahraa I. Abaza, Nouran M. Radwan, Ahmed R. Elazeem, Mervat IAbd Mohsen, Wael Abdel Moshrif, Abdel Hafeez Mohamed, Eman F. Aglan, Loay I. Senara, Soha Ibrahim, Maha E. Khalifa, Iman Owaidy, Rasha El Fakharany, Noha El. Mohammed, Reem Hamdy A. Gheita, Tamer A. Rheumatol Int Observational Research OBJECTIVES: The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. METHODS: The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. RESULTS: 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). CONCLUSIONS: The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00296-021-04941-0. Springer Berlin Heidelberg 2021-07-09 2021 /pmc/articles/PMC8269986/ /pubmed/34244818 http://dx.doi.org/10.1007/s00296-021-04941-0 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Observational Research
Hammam, Nevin
Tharwat, Samar
Shereef, Rawhya R. El
Elsaman, Ahmed M.
Khalil, Noha M.
Fathi, Hanan M.
Salem, Mohamed N.
El-Saadany, Hanan M.
Samy, Nermeen
El-Bahnasawy, Amany S.
Abdel-Fattah, Yousra H.
Amer, Marwa A.
ElShebini, Emad
El-Shanawany, Amira T.
El-Hammady, Dina H.
Noor, Rasha Abdel
ElKhalifa, Marwa
Ismail, Faten
Fawzy, Rasha M.
El-Najjar, Amany R.
Selim, Zahraa I.
Abaza, Nouran M.
Radwan, Ahmed R.
Elazeem, Mervat IAbd
Mohsen, Wael Abdel
Moshrif, Abdel Hafeez
Mohamed, Eman F.
Aglan, Loay I.
Senara, Soha
Ibrahim, Maha E.
Khalifa, Iman
Owaidy, Rasha El
Fakharany, Noha El.
Mohammed, Reem Hamdy A.
Gheita, Tamer A.
Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
title Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
title_full Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
title_fullStr Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
title_full_unstemmed Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
title_short Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt
title_sort rheumatology university faculty opinion on coronavirus disease-19 (covid-19) vaccines: the vaxurvey study from egypt
topic Observational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269986/
https://www.ncbi.nlm.nih.gov/pubmed/34244818
http://dx.doi.org/10.1007/s00296-021-04941-0
work_keys_str_mv AT hammamnevin rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT tharwatsamar rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT shereefrawhyarel rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elsamanahmedm rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT khalilnoham rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT fathihananm rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT salemmohamedn rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elsaadanyhananm rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT samynermeen rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elbahnasawyamanys rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT abdelfattahyousrah rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT amermarwaa rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elshebiniemad rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elshanawanyamirat rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elhammadydinah rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT noorrashaabdel rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elkhalifamarwa rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT ismailfaten rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT fawzyrasham rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elnajjaramanyr rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT selimzahraai rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT abazanouranm rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT radwanahmedr rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT elazeemmervatiabd rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT mohsenwaelabdel rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT moshrifabdelhafeez rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT mohamedemanf rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT aglanloayi rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT senarasoha rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT ibrahimmahae rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT khalifaiman rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT owaidyrashael rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT fakharanynohael rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT mohammedreemhamdya rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT gheitatamera rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt
AT rheumatologyuniversityfacultyopiniononcoronavirusdisease19covid19vaccinesthevaxurveystudyfromegypt